CBO report supports cost savings nature of the Preserve Access to Affordable Generic Drugs Act

Just as the Pfizer/Ranbaxy agreement that delayed the introduction of generic Lipitor winds to a close, the Preserve Access to Affordable Generic Drugs Act (S.27) has been referred out of committee.  The bill is specifically designed to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, a strategy drug companies have used to deal with the “patent cliff.”

Now the CBO has issued a report that estimates the bill would save the U.S. budget $4.8B over a ten year period.